Retour

Explorez tous les épisodes du podcast Dr. GPCR Podcast

Plongez dans la liste complète des épisodes de Dr. GPCR Podcast. Chaque épisode est catalogué accompagné de descriptions détaillées, ce qui facilite la recherche et l'exploration de sujets spécifiques. Suivez tous les épisodes de votre podcast préféré et ne manquez aucun contenu pertinent.

Rows per page:

1–50 of 231

TitreDateDurée
Building GPCR Assays That Reflect Real Biology09 sept. 202600:56:21

The biggest signal is not the same as the truest one. Jane Lamerdin and Gaurav Agrawal of Eurofins DiscoverX on what actually makes a GPCR assay trustworthy.

Overexpress a receptor and you get a big, convenient readout that drifts away from what happens in a living cell. Across nearly three decades of building cell-based assays, Lamerdin and Agrawal have learned that physiological relevance, not raw expression, is the real benchmark, and increasingly it is what regulators expect too.

This conversation moves from the company's roots in cyclic AMP and arrestin biology to the receptors that refuse to yield an assay, the long road from a discovery screen to potency and lot release, and why the obesity drug wave brought the largest target class back to the front of drug discovery.

What you will take away:

  • Why physiological relevance beats maximal expression, and how that raises the technical bar
  • What it takes to move one assay from discovery all the way to potency and lot release
  • Why some GPCRs, from adhesion receptors to orphans stuck in the ER, refuse to cooperate
  • How decades of documented failures keep a portfolio from reinventing dead ends
  • Why obesity and GLP-1 biology put GPCRs back at the center of drug discovery


Dr. GPCR Ecosystem: https://www.ecosystem.drgpcr.com/
Eurofins DiscoverX: https://www.ecosystem.drgpcr.com/eurofins-discoverxMembership and Pricing: https://www.ecosystem.drgpcr.com/university-pricing



He Left Stanford to Decode Adhesion GPCRs - Antony Boucard26 août 202601:40:33

Adhesion GPCRs are the largest receptors in the human genome — and until recently, no one was certain they coupled to G proteins at all. Boucard is working to change that, one synapse at a time.

Antony Boucard didn't plan to be a scientist. He was heading toward medical school — fresh from social work in Nicaragua, where he built wood-burning ovens for women's cooperatives, and years of service in the Canadian Navy Reserve — when a summer in a biochemistry lab changed his trajectory entirely. He turned down his medical school acceptance and never looked back.

After graduate training at the Université de Sherbrooke, a postdoctoral fellowship in Thomas Südhof's Nobel Prize-winning lab (first at UT Southwestern in Dallas, then at Stanford) opened a new research direction: the molecular code governing synapse formation. A chance experiment — testing whether a cell adhesion molecule he was studying might bind to a GPCR — yielded a result that Südhof himself didn't believe at first. Both proteins, it turned out, were independently known to bind alpha-latrotoxin, the toxin from black widow spider venom. No one had thought to ask whether they interacted with each other. That question has defined Boucard's lab ever since.

Now at UNAM in Mexico City — where no lab was working on adhesion GPCRs when he arrived — he is building a research program that connects these colossal, largely orphan receptors to synapse specificity, addiction, autism, schizophrenia, bipolar disorder, and cancer. The conversation covers the science, the serendipitous path behind it, and what it looks like to pioneer a research field in a place no one expected.

  • Why adhesion GPCRs are structurally unlike any other GPCR family — sprawling N-terminal domains, autoproteolytic processing, up to 1,000 amino acids — and what made them so difficult to work with for so long
  • How alpha-latrotoxin from black widow spider venom became the unexpected clue connecting a cell adhesion molecule and a GPCR into the same intercellular complex
  • What synapse formation reveals about adhesion GPCR function — and how addiction, autism, schizophrenia, and cancer all converge on the same receptor biology
  • Why Boucard left Stanford and UT Southwestern to build a lab at UNAM, and what it means to recruit from scientific communities that larger institutions overlook
  • The assays the lab uses to probe adhesion GPCR biology: BRET, FRET, microscopy, flow cytometry, and custom protein engineering strategies to solubilize membrane-anchored ligands
  • The dream tool he can't build yet — a nanoscale real-time camera navigating the cell surface — and why cryo-EM snapshots still miss the most important part


Dr. GPCR Ecosystem: https://www.ecosystem.drgpcr.com/

The GPCR Nobody Has Learned to Drug Yet — Schulte12 août 202601:08:53

Frizzled receptors look like GPCRs — but the field is split on whether they actually are. Gunnar Schulte has spent 25 years building the case, one receptor at a time.

Schulte is a professor at Karolinska Institute in Stockholm, where his lab investigates Wnt–frizzled signaling at the molecular level. His research maps G-protein coupling specificity across all 10 frizzled subtypes, develops conformational biosensors to detect receptor activation, and searches for small molecules that could finally make frizzled receptors pharmacologically tractable. In this conversation, he walks through the evidence — what the conformational data show, why the Wnt ligand problem has stalled the field for decades, and how a compound originally designed for Smoothened became the closest thing frizzled pharmacology has to a starting point.

  • Why each frizzled subtype couples to a different G protein — and why that distinction changes how the field should think about targeting them
  • Why 19 Wnt ligands remain almost impossible to work with, and what the lipid modification problem costs drug discovery
  • How SAG1.3, a Smoothened agonist, became the first small molecule to activate frizzled 6 as a partial agonist
  • What conformational sensors reveal about frizzled activation — and why Schulte considers this his strongest argument for their GPCR identity
  • How disheveled and G proteins may compete for receptor access through conformational selection


Dr. GPCR Ecosystem: https://www.ecosystem.drgpcr.com/

The Off-Rate Nobody Measured22 juil. 202602:13:57

Same binding affinity. Same target. One compound worked in vivo. The other did nothing. The answer was how long each molecule stayed on the CRF receptor — seven hours versus fifteen minutes — and no one had thought to measure it.


Sam Hoare spent 15 years at Neurocrin Biosciences before founding PharmaChanics, a pharmacology data analysis consultancy built on one conviction: most GPCR teams are collecting data they don't know how to analyze. In this conversation, Hoare walks through the off-rate discovery that redirected an entire drug program, the signaling kinetics framework he developed to fill a gap no one had formally acknowledged, and what it actually takes to move from industry scientist to independent consultant. Along the way: why GPCRs are the most tractable system in pharmacology — and why that still isn't enough if the analysis is wrong.

  • How receptor residence time — not affinity — determined which CRF compound reached Phase 2
  • Why time-course signaling data is routinely collected but almost never analyzed with the rigor applied to dose-response curves
  • What 15 years of GPCR drug discovery taught Hoare about the gap between understanding a receptor and making a drug for it
  • How early-career researchers can leverage deep target expertise to build a consulting practice
  • The three aha moments that have kept a pharmacological data analyst motivated across a 30-year career


Dr. GPCR Ecosystem: https://www.ecosystem.drgpcr.com/Membership & Pricing: https://www.ecosystem.drgpcr.com/university-pricingWeekly News: https://www.ecosystem.drgpcr.com/gpcr-weekly-news

The Accident That Built the GPCR Field — Bob Lefkowitz08 juil. 202601:30:36

Lefkowitz was told in 1973 that hormone receptors were a figment of his imagination. The work that proved otherwise became the molecular foundation of GPCR pharmacology.

Nobel laureate Robert Lefkowitz traces the full arc of GPCR discovery — from developing the first radioligand for the beta-adrenergic receptor to purifying it, cloning it, and watching a sequencing run reveal structural homology with rhodopsin that nobody in the field had predicted. That 1986 paper established the GPCR superfamily. The same system yielded the GRK family and the beta-arrestins. This conversation is also about the human architecture behind that science: how a Vietnam War draft assignment in 1968 redirected a physician toward a question the field wasn't sure was real, what 18 months of unbroken failure at the NIH taught him about research, and why he argues that if 50% of your experiments succeed, you are not working on hard enough problems.

  • How a Vietnam War draft sent a physician to the NIH — and gave rise to 50 years of GPCR receptor pharmacology
  • Why Lefkowitz chose the beta-adrenergic system, and why he considers it the smartest scientific decision of his career
  • The cloning race against Genentech: the "stupid idea" that worked and the intronless gene that ended the competition
  • High output vs. low output failure — how to find the research territory between trivial problems and intractable ones
  • What the Nobel call at 5 AM actually felt like: not jubilation, but relief — and a tear when he learned who he'd share it with


Dr. GPCR Ecosystem: https://www.ecosystem.drgpcr.com/

The GPCR Antibody Nobody Could Validate - GeneTex - Alexander Ball & Chia-Yi Lin17 juin 202600:41:04

Most GPCR antibody failures are silent. The signal looks clean, the band is there, the experiment moves forward - until someone runs a knockout control and the signal is still there. Lin and Ball have spent years building reagents for exactly this problem, and this conversation gets into the details of what reliable GPCR antibody characterization actually requires.

Chia-Yi Lin and Alexander Ball are scientists-turned-industry professionals at GeneTex, a company that has shifted its entire new antibody production to recombinant monoclonal technology since 2019. In this conversation, they trace the arc from GeneTex's founding by cancer biology researchers in 1990s Texas to its current position as a growing source of characterized GPCR research reagents.

The discussion covers why GPCR targets are especially difficult immunogen design problems, what five-pillar antibody characterization looks like for receptors like LGR5 and the chemokine receptor family, and why the word "characterized" may be more scientifically honest than "validated" when describing what an antibody data sheet actually tells you. Ball's path from medicine to the bench to industry - and Lin's from stem cell biology to leading international operations at GeneTex - brings a rare dual perspective to a problem that most researchers only see from one side.


Key topics covered:

  • Why GPCR family homology - including the 75% sequence identity between CXCR1 and CXCR2 - makes immunogen selection the critical upstream decision in antibody development, often determining success or failure before a single experiment is run


  • What five-pillar characterization looks like in practice: KO and KD validation, comparable antibody testing, cell fractionation, tissue orthogonal testing, and GPCR virion arrays from CDI Labs


  • How recombinant monoclonal antibodies solve the batch variability problem that polyclonal production cannot - and why a sequence defined in a plasmid changes reproducibility for the entire field


  • The LGR5 story: how one leucine-rich repeat GPCR critical to intestinal stem cell biology became GeneTex's defining early challenge - and why Ball's company president went pale when the target came up


  • Why Ball and Lin encourage researchers to contact the company directly before purchasing, what questions to ask, and how a free GPCR antibody sample program is actively connecting the community with reagents that need real-system testing


Dr. GPCR Links and Resources

Three Adhesion GPCRs and No Rulebook - Beatriz Blanco27 mai 202600:44:20

Most receptors come with a history. Remulate came with a name — and almost nothing else. Dr. Beatriz Redondo, group leader at the University of Leipzig, has spent the last nine years building the first systematic characterization of adhesion GPCRs in Drosophila, including three receptors so new they were named after condiments. What she's constructing isn't just a receptor profile — it's a method for doing discovery when the tools don't exist yet.


Dr. Redondo uses CRISPR, genetic tagging, and in vivo behavioral assays to place and characterize adhesion GPCRs in a system where generations turn over in weeks. Her work on remulate — a neuronal adhesion GPCR with a human ortholog linked to vascular malformations and blood-brain barrier dysfunction — is among the first of its kind in any organism.


Key takeaways:

  • Why Drosophila remains a productive system for receptor discovery in the genomics era
  • How CRISPR and epitope tagging replace antibody-based tools for understudied GPCRs
  • What nocifensive behavior in larvae reveals about remulate's neuronal function
  • How basic science in an insect model connects to vertebrate disease biology
  • What it looks like to characterize a receptor from scratch — with no prior literature to build on


Dr. GPCR University — live and on-demand courses for scientists working on real discovery problems: https://www.ecosystem.drgpcr.com/gpcr-university


This episode is supported by Eurofins DiscoverX and GeneTex: https://www.ecosystem.drgpcr.com/eurofins-discoverx | https://www.ecosystem.drgpcr.com/genetex

Chimeric GPCRs: Why the Easy Designs Fail — Charlotte Crauwels13 mai 202600:47:40

What if two nearly identical GPCRs make a worse chimera than two receptors from completely different classes? Charlotte Crauwels is building computational tools to find out why — and to predict which designs will work before they reach the bench.

Crauwels develops in silico pipelines for chimeric GPCR design at the Free University of Brussels. Her work sits at the interface of computational prediction and experimental validation, addressing a problem the field has struggled with for decades: chimeric constructs are powerful but unpredictable, and the data surrounding them is scattered, inconsistently named, and poorly annotated. After spending over a year collecting and standardizing published chimeric GPCR data, she built GPCR ChimeraDB — one of the first public databases dedicated to these constructs.


Key takeaways:

  • How chimeric GPCRs can deorphanize receptors and reveal signaling pathways that were previously inaccessible
  • Why computational ranking of chimeric candidates replaces trial-and-error in the lab
  • What inconsistent nomenclature and missing annotations cost the field — and how better data sharing changes the game
  • Why the feedback loop between computational and experimental scientists is non-negotiable for GPCR research


Dr. GPCR Links & Resources

The Beta-2 Agonist That Doesn't Stop Working — Tore Bengtsson06 mai 202600:45:55

Every beta-2 agonist ever tested for muscle growth hits the same wall: desensitization. Dr. Tore Bengtsson built one that doesn't.

A professor at Stockholm University and founder of Atrogi, Dr. Bengtsson has spent 25 years studying how beta-adrenergic receptors regulate metabolism, muscle, and brown fat. His lab developed 1,500+ compounds that activate beta-2 through distinct signaling pathways, and one is now heading into Phase 2 clinical trials. He shares how a "failed" experiment cracked the problem, why incretins only address half of metabolic disease problems, and what muscle loss after 50 means for drug discovery strategy.


Key takeaways:

  • Classical beta-2 agonists fail because desensitization shuts down the response
  • Selectively activating specific signaling pathways from one receptor can produce entirely different outcomes
  • Incretins reduce energy intake — but the energy expenditure side remains wide open
  • The correlation between muscle mass and longevity is one of the most underserved areas in metabolic medicine

🔗 Dr. GPCR Ecosystem: https://www.ecosystem.drgpcr.com/

🎓 Membership & Pricing: https://www.ecosystem.drgpcr.com/university-pricing

📰 Weekly News: https://www.ecosystem.drgpcr.com/gpcr-weekly-news

One Molecule, Two Opioid Receptors - Joseph Kim29 avr. 202600:50:28

Dr. Joseph Kim solved cryo-EM structures of mu and kappa opioid receptors bound to the same small molecule — and found it does something different at each one.

In this conversation, Dr. Kim walks through his transition from cryo-electron tomography to GPCR structural biology in Ashish Manglik's lab at UCSF, the strategy behind solving inactive-state receptor structures, and why his favorite GPCR — the galanin receptor — has resisted every small-molecule screen thrown at it.


Key takeaways:

  • How one molecule acts as an antagonist at mu and an inverse agonist at kappa
  • Why the galanin receptor's peptide binding mode blocks conventional drug discovery
  • What it takes to switch fields with no prior biochemistry training
  • How building tools on "vanilla" GPCRs prepares you for exotic targets


🔬 Dr. GPCR Ecosystem: https://www.ecosystem.drgpcr.com/

💰 Membership & Pricing: https://www.ecosystem.drgpcr.com/university-pricing

📰 Weekly News: https://www.ecosystem.drgpcr.com/gpcr-weekly-news

Can Simulations Predict GPCR Ligand Bias?18 mars 202600:54:48

How does ligand binding at the extracellular pocket of a GPCR reshape signaling on the intracellular side?

Biased agonism is often measured through pathway activation assays, but the structural origin of ligand bias remains difficult to trace. Can molecular simulations reveal the communication routes that link ligand binding to G protein or arrestin signaling?

In this conversation, computational biologist Anita Niveda explores how molecular dynamics and network analysis can map allosteric communication within GPCRs—revealing how microscopic structural pathways relate to macroscopic signaling outcomes.

From discovering bioinformatics as an undergraduate to developing computational methods for quantifying ligand bias, the discussion moves through the scientific thinking behind modeling receptor signaling, collaborations between academia and industry, and how computational tools are becoming predictive instruments in drug discovery.


Key Topics in This Episode

  • How molecular dynamics simulations reveal communication pathways connecting ligand binding sites to G protein or arrestin interfaces

  • Why mapping allosteric communication networks helps explain biased agonism in GPCR signaling

  • What computational strategies can quantify ligand bias directly from receptor structures

  • How receptor subtype selectivity emerges from subtle structural and dynamic differences in binding pockets

  • Why academic–industry collaborations can accelerate method development in receptor pharmacology

  • What career decisions shape the path from computational biology training to drug discovery roles


Timestamps


0:00 A structural question behind ligand bias
1:30 Introduction and scientific background
3:40 Discovering bioinformatics and computational biology
7:30 First encounters with GPCR structural biology
9:40 Finding and choosing a postdoctoral lab
16:40 Entering GPCR research and allosteric communication
18:20 Quantifying ligand bias using simulations
20:00 Mapping signaling pathways through receptor residues
23:30 Academic–industry collaboration with Boehringer Ingelheim
27:00 Moving from academia to industry research
35:00 Interviewing and transitioning into biotech
45:00 Aha moments in computational GPCR research
50:00 The diversity of GPCR families and signaling biology


Keywords: GPCR podcast, GPCR signaling, biased agonism, drug discovery, receptor pharmacology

Why Mosquitoes Hunt You: The GPCR Behind the Bite - Laura Duvall04 mars 202600:51:05

Conserved neuropeptide Y GPCRs orchestrate both feeding and mating behaviors in mosquitoes, with direct translational parallels to human gut-brain signaling.


Quick Summary

Learn how receptor internalization and neuropeptide GPCR signaling underlie the regulation of mosquito host-seeking and reproduction. Dr. Laura Duvall details the use of CRISPR-based assay development and fluorescence-driven phenotyping to connect molecular manipulation to whole-animal behavior. Her approach provides actionable insights for gpcr drug discovery and tools to dissect homologous pathways across model systems, with implications for pharmacology research targeting vector-borne disease transmission.


Key Takeaways

  • Neuropeptide Y GPCRs modulate both host attraction and mating in Aedes aegypti.

  • CRISPR and fluorescence assays enable precise behavioral phenotyping in vivo.

  • GPCR-targeted compounds designed for humans can modulate mosquito receptors.

  • NPY receptor expression in mosquito gut mirrors mammalian gut-brain signaling axes.

  • Automated behavioral assays combined with machine learning sharpen data resolution and reduce human bias.


Dr. GPCR Links & Resources

Explore essential resources:

Advance your research—discover the power of Dr. GPCR Premium.


About the Guest

Dr. Laura Duvall earned her B.A. in Biochemistry and Biological Basis of Behavior from the University of Pennsylvania, followed by a PhD at Washington University in St. Louis, where she explored neuropeptide regulation of circadian behavior in Drosophila. Transitioning from fruit flies to mosquitoes, she pursued postdoctoral research at Rockefeller University with Leslie Vosshall, focusing on the molecular regulation of feeding and mating behaviors in Aedes aegypti. In 2019, she established her independent laboratory at Columbia University's Department of Biological Sciences and the Zuckerman Institute. Dr. Duvall’s work is recognized by awards including the Beckman Young Investigator Award, Klingenstein-Simons Fellowship in Neuroscience, and the Pew Scholars Program, reflecting her drive to unravel the complex signaling mechanisms that govern mosquito and broader animal behavior.


Guest on The Web

GPCR Location and Lipid Raft Signaling18 févr. 202600:37:01

Key Takeaways

How does the precise localization of GPCRs in lipid rafts reshape drug discovery strategy? Examine implications for functional assays and therapeutic innovation.

Explore the pivotal role of GPCR-lipid raft compartmentalization in receptor signaling, desensitization, and pharmacology research. Dr. Keyvan Sedaghat discusses assay approaches, regulatory mechanisms, and the translational impact of bitter taste receptors beyond sensory biology.

Leveraging decades of experience in assay development and database creation, he offers actionable insights for researchers optimizing GPCR drug discovery pipelines.

  • Compartmentalization of GPCRs in lipid rafts directly influences receptor signaling and drug response.

  • Desensitization pathways of dopamine D1 receptors depend on precise phosphorylation domains—challenging classical paradigms.

  • Bitter taste receptors demonstrate functional relevance in non-gustatory tissues with emerging therapeutic applications.

  • Database-driven research accelerates the identification of receptor-microdomain interactions for novel targets.

  • Integration of computational modeling and biochemical validation is essential for advancing GPCR assay strategies.


Dr. GPCR Links & Resources

Access the Dr. GPCR Ecosystem at https://www.ecosystem.drgpcr.com/ for community, tools, and databases.

Details on Membership & Pricing: https://www.ecosystem.drgpcr.com/university-pricing

GPCR Weekly News: https://www.ecosystem.drgpcr.com/gpcr-weekly-news

Explore Dr. GPCR Premium for expanded translational resources and networking.


About the Guest

Dr. Keyvan Sedaghat holds a pharmacy degree and a PhD in cellular and molecular medicine, specializing in pharmacology, from the University of Ottawa. With over two decades of academic experience, he has served as a professor, senior lecturer, and chief scientific officer in the pharmaceutical and cosmetic industries. Dr. Sedaghat’s work spans peer-reviewed publications and editorial roles across journals in molecular pharmacology, cell signaling, and G protein-coupled receptors. His scientific drive centers on unraveling molecular mechanisms underlying GPCR function and translating those findings into effective teaching, research, and drug discovery strategies.


Guest on the Web:

Choosing the Right GPCR Assays for Translational Drug Discovery 18004 févr. 202600:51:00

Episode Summary


Potent in vitro hits often fail in vivo—Martin Marro details how robust assay choice and pathway deconvolution can revive GPCR drug discovery programs.

Listeners will learn practical approaches to assay development for GPCR drug discovery, the pitfalls of calcium readouts, and how identifying pathway bias impacts translational success. Dr. Marro shares his experience bridging in vitro–in vivo gaps, refining selection flowcharts, and leveraging pharmacology research to drive clinical candidates. His strategic perspective is rooted in years of leading multimodal discovery teams in pharma and biotech.


Key Takeaways


  • Assay selection critically shapes the trajectory from hit to clinic.
  • Calcium and IP1 assays may not predict in vivo efficacy for all Gq-coupled receptor targets
  • Alternative pathway analysis may be essential for mechanism elucidation.
  • Persistence in probing beyond standard readouts can rescue high-profile discovery programs.
  • Team structure and collaborative problem-solving are pivotal in resolving translational bottlenecks.


Explore Dr. GPCR Resources


- Dr. GPCR Ecosystem

- Membership & Pricing

- Weekly News


Explore the full depth of GPCR resources, events, and member-exclusive tools with Dr. GPCR Premium.


About the Guest


Dr. Martin Marro leads the Cell Pharmacology group in the DOCTA division at Lilly’s Seaport Innovation Center in Boston, MA. Trained as a pharmacologist, Dr. Marro has accumulated over 20 years of experience spanning large pharmaceutical firms—including GSK, Novartis, and Lilly—and innovative biotech such as Tectonic Therapeutic. He holds deep expertise in early drug discovery across small molecules, peptides, and antibody therapeutics for metabolic, cardiovascular, and gastrointestinal diseases.

Dr. Marro’s research has been central to the discovery and characterization of multiple clinical candidates, with a focus on GPCR target validation, receptor pharmacology, and translational assay strategies. He played a key role in patenting and developing novel fatty acid-conjugated GLP-1 receptor agonists. Driven by the challenge of translating robust in vitro science into clinical proof-of-concept, Dr. Marro’s leadership continues to impact the field of GPCR drug discovery.


Keywords: gpcr podcast, assay development, pharmacology research.

How Academia–Industry Collaboration Is Scaling GLP-1 Receptor Tools | Dr. GPCR Podcast #17917 déc. 202500:55:06

GPCR tools don’t move the field forward unless researchers can actually use them. This episode breaks down how collaboration turns probes into progress.

Summary


In the final episode of this series, David Hodson, Johannes Broichhagen, and Maria Majellaro unpack how academic labs and Celtarys Research partnered to scale fluorescent probes, improve assay development, and support gpcr drug discovery. The conversation spans receptor internalization, fluorescence assays, tech transfer realities, and why tool availability—not just invention—drives translational pharmacology research.

Key takeaways

  • Why accessibility defines the real impact of GPCR tools

  • How industry enables scalable assay development

  • Lessons from receptor internalization studies in complex tissues

  • What makes academia–industry collaborations actually work

Read more here: https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/scaling-glp-1-receptor-tools-through-academia–industry-collaboration

Imaging GPCRs in Action: Chemical Probes for Next-Level Discovery | Dr. Johannes Broichhagen #17803 déc. 202500:38:58

Chemical probes are reshaping how we map GLP-1R in real time — revealing receptor pools antibodies can’t reliably capture.


This is Episode 2 of a 3-part GPCR tool-development series created in partnership with Celtarys Research.


Summary:


Dr. Johannes Broichhagen aka JB breaks down the design logic behind fluorophore-linked peptides, assay trade-offs, and what true receptor internalization looks like in live tissue. A concise masterclass in assay development and GPCR drug discovery.


What you’ll learn:


• Why antibody variability pushed JB toward chemical probe engineering

• The design logic behind Luxendin-based fluorescent tools — and how structure guides function

• What “good assay development” looks like when cells, tissue, and probe behavior collide

• Behind-the-scenes stories from the collaboration with David Hodson

• Why parallelized experiments matter for reproducibility and signal quality

• How small-molecule probes outperform antibodies in live-cell and tissue imaging

• The surprising breakthroughs that shifted JB’s entire research trajectory

• Future directions: multi-color GPCR mapping, AI-guided ligand design, and in vivo chemical biology


Dr GPCR Links & Resources:

• Dr. GPCR Ecosystem: https://www.ecosystem.drgpcr.com/


• Membership & Pricing: https://www.ecosystem.drgpcr.com/university-pricing• Weekly News: https://www.ecosystem.drgpcr.com/gpcr-weekly-news

Mapping GLP-1 & GIP Receptors in Metabolic Disease with Dr. David Hodson - Episode 17719 nov. 202500:55:06

Precise receptor mapping is reshaping how we understand incretin biology. David Hodson explains how GPCR-targeted chemical probes reveal where GLP-1 and GIP receptors actually signal across pancreas and brain—and what this means for metabolic drug design.
Learn how these tools refine gpcr drug discovery, clarify receptor internalization, and guide next-gen therapeutics.
🎓 Join Dr. GPCR Premium for exclusive episodes + research tools → https://www.ecosystem.drgpcr.com/

Inside Monash: Organized Signaling, Real Impact12 nov. 202500:47:20

What makes Monash a model for modern pharmacology? Dr. Michelle Halls reveals how collaboration, mentorship, and receptor organization shape today’s GPCR breakthroughs — from femtomolar signaling to cancer biology. A look inside a lab culture built on precision, openness, and impact.


👉  Watch the complete episode: https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/leadership-luck-and-gpcr-signaling

🎓 Join Dr. GPCR Premium for exclusive episodes + research tools → https://www.drgpcr.com/premium

Model. Predict. Discover. with Dr. Jens Carlsson | Dr. GPCR Podcast #17522 oct. 202500:44:55

Predicting, not just explaining, can change how we design GPCR-targeted drugs. Jens Carlsson reveals how modeling bridges structure, function, and pharmacology.


Hear how predictive simulations shape assay development, GPCR drug discovery, and collaborations across disciplines.


🎓 Join Dr. GPCR Premium for exclusive episodes + research tools → https://www.ecosystem.drgpcr.com/gpcr-university-pricing

 

Watch the complete episode at https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/model-predict-discover

From Rare Earth Probes to Internalization Assays: The pHSense Story with Dr. Eric Trinquet from Revvity | Dr. GPCR Podcast #17422 sept. 202500:42:12

🔬 What if you could track GPCR internalization—no wash, high-throughput, and in endogenous systems?


Discover how Dr. Eric Trinquet and Revvity built pH Sense, a next-gen fluorescence assay that redefines receptor internalization workflows. Learn assay trade-offs, tool design, and how to decode GPCR behavior with precision.


🎓 Join Dr. GPCR Premium for exclusive episodes + research tools → https://www.ecosystem.drgpcr.com/gpcr-university-pricing


Watch the complete episode at https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/from-rare-earth-probes-to-real-internalization-assays-the-ph-sense-story

From Curiosity to Breakthrough: Ajay Yekkirala on GPCR Innovation | Dr. GPCR Podcast #17302 sept. 202501:03:26

What if a failed med school plan led to a biotech breakthrough?
Ajay Yekkirala shares how GPCRs, AI, and scientific curiosity are reshaping pain therapeutics — and what it really takes to build better medicines.
Watch the video version of this podcast episode: What if a failed med school plan led to a biotech breakthrough?
Ajay Yekkirala shares how GPCRs, AI, and scientific curiosity are reshaping pain therapeutics — and what it really takes to build better medicines.
Watch the video version of this podcast episode: https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/from-curiosity-to-breakthrough-ajay-yekkirala-on-gpcr-innovation

Xylazine, Fentanyl, and the Fight for Breath with Catherine Demery19 août 202501:00:56

When fentanyl slows your breath and xylazine traps it, the clock starts ticking.

PhD candidate Catherine Demery takes us inside her fight to understand how fentanyl and xylazine shut down breathing in different ways—work that blends GPCR pharmacology, animal models, and real-time street data to combat the opioid crisis.
Watch the video version of this podcast episode: Ep 172 with Catherine Demery

Smells Like GPCR Spirit: Cracking Olfactory Codes with Alessandro Nicoli / Dr. GPCR Podcast #17105 août 202500:34:29


Watch the video version of this podcast episode.

https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-171-with-alessandro-nicoli


---------------------------------

Become a #DrGPCR Ecosystem Member

---------------------------------


Imagine a world in which the vast majority of us are healthy.


The #DrGPCR Ecosystem is all about dynamic interactions between us working towards exploiting the druggability of #GPCRs. We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.


---------------------------------


To build our #GPCR Ecosystem, we created various enabling outlets.


Are you a #GPCR professional?


GPCRs and the Science Behind Pain & Recovery with Dr. Alex Serafini / Dr. GPCR Podcast #17022 juil. 202501:02:27

Watch the video version of this podcast episode.

https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-170-with-dr-alex-serafini


---------------------------------

Become a #DrGPCR Ecosystem Member

---------------------------------


Imagine a world in which the vast majority of us are healthy.


The #DrGPCR Ecosystem is all about dynamic interactions between us working towards exploiting the druggability of #GPCRs. We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.


---------------------------------


To build our #GPCR Ecosystem, we created various enabling outlets.


Are you a #GPCR professional?


GPCR Pharmacology, Career Twists & Serendipity with Dr. Sokhom Pin / Dr. GPCR Podcast #16908 juil. 202500:56:54

Watch the video version of this podcast episode.

https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-169-with-dr-sokhom-pin


---------------------------------

Become a #DrGPCR Ecosystem Member

---------------------------------


Imagine a world in which the vast majority of us are healthy.


The #DrGPCR Ecosystem is all about dynamic interactions between us working towards exploiting the druggability of #GPCRs. We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.


---------------------------------


To build our #GPCR Ecosystem, we created various enabling outlets.


Are you a #GPCR professional?


Baking Molecules, Building Probes: When Chemists Think Like Biologists with Dr. Maria Majellaro / Dr. GPCR Podcast 16810 juin 202501:05:41

Watch the video version of this podcast episode:

https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-168-with-dr.-maria-majellaro-from-celtarys


Visit Celtarys' website in the Ecosystem: https://www.ecosystem.drgpcr.com/celtarys-research-dr-gpcr-ecosystemRead the DrGPCR x Celtarys Partnership Press Release: https://www.ecosystem.drgpcr.com/post/dr-gpcr-and-celtarys-research-join-forces-to-expand-access-to-innovative-gpcr-toolsLearn more about Celtarys Research: https://www.celtarys.com/


---------------------------------

Become a #DrGPCR Ecosystem Member

---------------------------------


Imagine a world in which the vast majority of us are healthy.


The #DrGPCR Ecosystem is all about dynamic interactions between us working towards exploiting the druggability of #GPCRs. We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.


---------------------------------


To build our #GPCR Ecosystem, we created various enabling outlets.


Are you a #GPCR professional?


Hacking GPCRs: Tools, Tech & Drug Discovery w/ Drs. Tom Sakmar & Ilana Kotliar / Dr.GPCR Podcast 16727 mai 202500:39:01

Watch the video version of this podcast episode.

https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-167-with-tom-sakmar-%26-ilana-kotliar


---------------------------------

Become a #DrGPCR Ecosystem Member

---------------------------------


Imagine a world in which the vast majority of us are healthy.


The #DrGPCR Ecosystem is all about dynamic interactions between us working towards exploiting the druggability of #GPCRs. We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.


---------------------------------


To build our #GPCR Ecosystem, we created various enabling outlets.


Are you a #GPCR professional?


When to Walk, When to Run: Lessons from the GPCR Trenches with Dr. Ben Clements / Dr.GPCR Podcast 16613 mai 202500:49:49

Episode 166 of the Dr. GPCR Podcast features Benjamin Clements, a postdoctoral fellow at the University of Michigan, who brings fresh insight into the therapeutic promise of GPCRs — particularly in the context of opioid pharmacology. With a background in pharmaceutical sciences and neuroscience, Ben now focuses on positive allosteric modulators (PAMs) targeting the mu-opioid receptor, aiming to preserve opioid analgesia while reducing harmful side effects like respiratory depression and addiction.In this episode, Ben and Dr. Yamina Berchiche discuss how a passion for translational science led him to investigate chronic pain models, including neuromas, where opioids traditionally fail. His lab’s preliminary findings — including a tenfold improvement in methadone efficacy — highlight the potential of GPCR-targeted allosteric modulators to change the treatment landscape for intractable pain conditions. These discoveries are the result of collaborative, curiosity-driven science in a lab culture that values both rigor and levity.Ben also shares his perspective on learning “old-school” assays like radioligand binding and GTPγS, emphasizing their enduring value even amid advanced high-throughput techniques. The conversation touches on mentorship, imposter syndrome, and the critical importance of creating space for new voices in the GPCR field. As Ben puts it:“Academia is all about knowing when to walk and when to run.”This episode is a powerful reminder of the role that early-career scientists play in shaping the future of GPCR drug discovery — blending pharmacological fundamentals with bold experimentation and a deep commitment to patient-centered science.Watch the complete episode at: https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-166-with-ben-clements


---------------------------------

Become a #DrGPCR Ecosystem Member

---------------------------------


Imagine a world in which the vast majority of us are healthy.


The #DrGPCR Ecosystem is all about dynamic interactions between us working towards exploiting the druggability of #GPCRs. We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.


---------------------------------


To build our #GPCR Ecosystem, we created various enabling outlets.


Are you a #GPCR professional?


Finance is Science too with Chuck DeWeese & Joe St. Germain / Dr.GPCR Podcast 16529 avr. 202500:49:44

In this episode of the Dr. GPCR Podcast, we step outside the lab to talk about what keeps research-driven organizations running behind the scenes: finance and operations. Yamina Berchiche is joined by Joe St. Germain and Chuck DeWeese from Company Launch Partners to discuss the real-world challenges of building startups and nonprofits—including Dr. GPCR itself. Joe shares his leap from corporate finance to launching a firm that supports early-stage ventures, while Chuck explains his journey from sales to becoming the behind-the-scenes problem-solver for mission-driven organizations.

What emerges is a compelling conversation about how science and finance are more similar than we think. Chuck and Joe explain how reconciling financial data mirrors the satisfaction of solving scientific puzzles. They also dive into the unique hurdles of accounting for grants, setting up sustainable financial systems, and choosing clients whose values align with their own. The episode bridges two traditionally separate worlds—science and business—by highlighting their shared reliance on structure, integrity, and impact.

At its core, the episode is about building things that last—with the right people. From hiring based on character and teachability to growing teams organically through trust and mentorship, Joe and Chuck share lessons that resonate far beyond finance. Whether you’re a GPCR scientist applying for a grant or a founder navigating early growth, this conversation is a powerful reminder that success is never solo—it’s built on relationships, purpose, and a clear sense of mission.


Watch the complete episode at: https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-165-with-chuckdeweese-joestgermain

Signals, pH, and Discovery: Cracking GPCR Mysteries with Dr. Ian Chronis / Dr.GPCR Podcast 16415 avr. 202500:49:33

In this science-focused episode of the Dr. GPCR podcast, we meet Dr. Ian Chronis, a freshly minted PhD from the University of Michigan. While his academic roots started in classical history and ancient Greek, Ian’s curiosity pulled him toward chemistry, then pharmacology, and eventually into the complex world of GPCR signaling. His story is a testament to the power of staying open to change and following emerging scientific questions wherever they lead.

Ian’s doctoral work focused on two key GPCR systems: the well-characterized β2-adrenergic receptor and the lesser-known proton-sensing receptor GPR65. In the former, he explored how PKA phosphorylation modulates receptor interactions and discovered a regulatory role for 14-3-3 proteins. But it’s GPR65 — a receptor that constitutively internalizes and signals from acidic endosomes — that has captured Ian’s attention and become the centerpiece of his current research. Unlike classical GPCRs, GPR65 uses non-canonical internalization mechanisms, presenting new opportunities to uncover novel biology.

The receptor’s ability to signal within the tumor microenvironment and immune cells makes it an emerging drug target, especially in cancer immunotherapy. However, there are still major gaps: no selective ligands, little clarity on its internalization machinery, and limited tools to modulate its function. Ian’s wish list? A high-affinity agonist and antagonist to begin untangling these questions. Until then, he's carefully optimizing pH-based assays and preparing for next steps in a postdoctoral lab focused on more physiological and therapeutic systems.

Whether he’s decoding novel trafficking pathways or reflecting on career strategy, Ian brings a balanced perspective that’s both ambitious and grounded. His advice to peers? Attend talks outside your field, learn constantly, and surround yourself with people who make science sustainable. This episode is a must-listen for those navigating the intersection of curiosity, technical rigor, and translational potential in the GPCR research community.


Watch the video version of this podcast episode:

https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-164-with-dr.-ian-chronis


---------------------------------

Become a #DrGPCR Ecosystem Member

---------------------------------


Imagine a world in which the vast majority of us are healthy.


The #DrGPCR Ecosystem is all about dynamic interactions between us working towards exploiting the druggability of #GPCRs. We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.


---------------------------------


To build our #GPCR Ecosystem, we created various enabling outlets.


Are you a #GPCR professional?


The Scientist’s Compass: From Academia to Entrepreneurship with Dr. Dmitry Veprintsev / Dr.GPCR Podcast 16301 avr. 202501:03:51

Ask the Right GPCR Question: A Conversation with Prof. Dmitry VeprintsevIn this episode, Yamina sits down with Prof. Dmitry Veprintsev, a molecular pharmacologist at the University of Nottingham, to discuss his scientific journey, GPCR research, and the intersection of academia and entrepreneurship.


Watch the video version of this podcast episode:

⁠https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-163-with-dr.-dmitry-⁠

---------------------------------

⁠Become a #DrGPCR Ecosystem Member⁠

---------------------------------

Imagine a world in which the vast majority of us are healthy.

Dr. GPCR is dedicated to fostering a collaborative ecosystem focused on GPCRs. By connecting researchers, sharing knowledge, and facilitating partnerships, the #DrGPCR Ecosystem provides resources to support advancements in GPCR drug discovery.

The ecosystem includes a variety of initiatives designed to inform and engage the scientific community, from courses and news updates to networking opportunities.

---------------------------------

The Secret Life of GPCRs: Why Location Matters with Dr. Gabriele Kockelkoren / Dr.GPCR Podcast 16218 mars 202500:58:46

Watch the video version of this podcast episode: https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-162-with-dr-gabriele-kockelkoren

---------------------------------

Become a #DrGPCR Ecosystem Member

---------------------------------

Imagine a world in which the vast majority of us are healthy.

Dr. GPCR is dedicated to fostering a collaborative ecosystem focused on GPCRs. By connecting researchers, sharing knowledge, and facilitating partnerships, the #DrGPCR Ecosystem provides resources to support advancements in GPCR drug discovery.

The ecosystem includes a variety of initiatives designed to inform and engage the scientific community, from courses and news updates to networking opportunities.

---------------------------------

You never know where your GPCR takes you with Dr. Brian Hudson / Dr.GPCR Podcast 16104 mars 202500:49:58

Watch the video version of this podcast episode.


https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-161-with-dr.-brian-hudson


---------------------------------


Become a #DrGPCR Ecosystem Member


---------------------------------


Imagine a world in which the vast majority of us are healthy.


The #DrGPCR Ecosystem is all about dynamic interactions between us working towards exploiting the druggability of # GPCRs. We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.


---------------------------------


To build our #GPCR Ecosystem, we created various enabling outlets.




Are you a #GPCR professional?


Developing new tools to uncover GPCR signaling patterns with Remi Janicot / Dr.GPCR Podcast 16020 févr. 202500:47:39

Watch the video version of this podcast episode.


https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-160-with-dr.-remi-janicot


---------------------------------


Become a #DrGPCR Ecosystem Member


---------------------------------


Imagine a world in which the vast majority of us are healthy.


The #DrGPCR Ecosystem is all about dynamic interactions between us working towards exploiting the druggability of # GPCRs. We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.


---------------------------------


To build our #GPCR Ecosystem, we created various enabling outlets.




Are you a #GPCR professional?


Translating computational approaches to GPCR biologists -Dr. Riccardo Capelli / Dr.GPCR Podcast 15906 févr. 202500:59:10

Register for the next Dr. GPCR University course before February 14th

https://www.ecosystem.drgpcr.com/event-details-registration/the-practical-assessment-of-signaling-bias Spots are limited!

_________


Watch the video version of this podcast episode.


https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-159-with-dr.-riccardo-capelli


---------------------------------


Become a #DrGPCR Ecosystem Member


---------------------------------


Imagine a world in which the vast majority of us are healthy.


The #DrGPCR Ecosystem is all about dynamic interactions between us working towards exploiting the druggability of # GPCRs. We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.


---------------------------------


To build our #GPCR Ecosystem, we created various enabling outlets.


Are you a #GPCR professional?

Anything but GPCRs - with Dr. Mikel Garcia-Markos / Dr. GPCR Podcast 15823 janv. 202500:55:40

Watch the video version of this podcast episode.


---------------------------------


Become a #DrGPCR Ecosystem Member


---------------------------------


Imagine a world in which the vast majority of us are healthy.


The #DrGPCR Ecosystem is all about dynamic interactions between us working towards exploiting the druggability of # GPCRs. We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.


---------------------------------


To build our #GPCR Ecosystem, we created various enabling outlets.




Are you a #GPCR professional?


⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Subscribe to #DrGPCR Monthly Newsletter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Listen and subscribe to #DrGPCR Podcasts⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

• • ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Listen and watch GPCR-focused scientific talks at #VirtualCafe⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.

Role of quantitative sciences in GPCRs with Dr. Nagarajan Vaidehi / Dr. GPCR Podcast 15710 janv. 202501:02:12

Watch the video version of this podcast episode.


---------------------------------


Become a #DrGPCR Ecosystem Member


---------------------------------


Imagine a world in which the vast majority of us are healthy.

The #DrGPCR Ecosystem is all about dynamic interactions between us working towards exploiting the druggability of # GPCRs. We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.


---------------------------------


To build our #GPCR Ecosystem, we created various enabling outlets.


Are you a #GPCR professional?

GPCR research is a privilege - Terry Kenakin15 août 202401:21:36

⁠⁠⁠⁠⁠⁠⁠Watch the video version of this podcast episode.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

-------------------------------------------

⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Become a #DrGPCR Ecosystem Member ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

-------------------------------------------

Imagine a world in which the vast majority of us are healthy.

The #DrGPCR Ecosystem is all about dynamic interactions between us working towards exploiting the druggability of # GPCRs. We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.

-------------------------------------------

To build our #GPCR Ecosystem, we created various enabling outlets.

-------------------------------------------

Are you a #GPCR professional?

Problem solving through GPCR data analysis - Sam Hoare08 août 202402:17:16

⁠⁠⁠⁠⁠⁠⁠Watch the video version of this podcast episode.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

-------------------------------------------

⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Become a #DrGPCR Ecosystem Member ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

-------------------------------------------

Imagine a world in which the vast majority of us are healthy.

The #DrGPCR Ecosystem is all about dynamic interactions between us working towards exploiting the druggability of # GPCRs. We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.

-------------------------------------------

To build our #GPCR Ecosystem, we created various enabling outlets.

-------------------------------------------

Are you a #GPCR professional?

Creating a support network to move GPCR biology forward - Evi Kostenis01 août 202401:04:57

⁠⁠⁠⁠⁠⁠⁠Watch the video version of this podcast episode.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

-------------------------------------------

⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Become a #DrGPCR Ecosystem Member ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

-------------------------------------------

Imagine a world in which the vast majority of us are healthy.

The #DrGPCR Ecosystem is all about dynamic interactions between us working towards exploiting the druggability of # GPCRs. We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.

-------------------------------------------

To build our #GPCR Ecosystem, we created various enabling outlets.

-------------------------------------------

Are you a #GPCR professional?

Always keep an open mind and trust your (GPCR) data and give back to others - Dr. Bryan Arey25 juil. 202401:08:13

⁠⁠⁠⁠⁠⁠⁠Watch the video version of this podcast episode.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

-------------------------------------------

⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Become a #DrGPCR Ecosystem Member ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

-------------------------------------------

Imagine a world in which the vast majority of us are healthy.

The #DrGPCR Ecosystem is all about dynamic interactions between us working towards exploiting the druggability of # GPCRs. We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.

-------------------------------------------

To build our #GPCR Ecosystem, we created various enabling outlets.

-------------------------------------------

Are you a #GPCR professional?

From a lecture on adrenaline function and GPCR, via RAMPs to becoming an industry leader - Dr. Fiona Marshall18 juil. 202400:48:51

⁠⁠⁠⁠⁠⁠⁠Watch the video version of this podcast episode.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

-------------------------------------------

⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Become a #DrGPCR Ecosystem Member ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

-------------------------------------------

Imagine a world in which the vast majority of us are healthy.

The #DrGPCR Ecosystem is all about dynamic interactions between us working towards exploiting the druggability of # GPCRs. We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.

-------------------------------------------

To build our #GPCR Ecosystem, we created various enabling outlets.

-------------------------------------------

Are you a #GPCR professional?


Capseicin, Ion channels, Smoothened and Class F GPCRs - Dr. Benjamin Myers11 juil. 202401:47:51

⁠⁠⁠⁠⁠⁠⁠Watch the video version of this podcast episode.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

-------------------------------------------

⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Become a #DrGPCR Ecosystem Member ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

-------------------------------------------

Imagine a world in which the vast majority of us are healthy.

The #DrGPCR Ecosystem is all about dynamic interactions between us working towards exploiting the druggability of # GPCRs. We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.

-------------------------------------------

To build our #GPCR Ecosystem, we created various enabling outlets.

-------------------------------------------

Are you a #GPCR professional?


DrGPCR Newsletter - Why come to the Adhesion GPCR workshop in October 202409 juil. 202400:25:46

Read the full version of the newsletter HERE: https://www.ecosystem.drgpcr.com/dr-gpcr-newsletter/24-06-dr-gpcr-newsletter ------------------------------------------- How can Users benefit Dr. GPCR Ecosystem? https://www.ecosystem.drgpcr.com/explore-individuals ------------------------------------------- How can Organizations benefit from Dr. GPCR Ecosystem? https://www.ecosystem.drgpcr.com/explore-organizations ------------------------------------------- Become a #DrGPCR Ecosystem Member https://www.ecosystem.drgpcr.com/plans-pricing ------------------------------------------- Imagine a world in which the vast majority of us are healthy. The #DrGPCR Ecosystem is all about dynamic interactions between us working towards exploiting the druggability of #GPCR's. We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together. To build our #GPCR Ecosystem, we created various enabling outlets. Individuals https://www.ecosystem.drgpcr.com/explore-individuals Organizations https://www.ecosystem.drgpcr.com/explore-organizations ------------------------------------------- Are you a #GPCR professional? - Subscribe to #DrGPCR monthly newsletter http://www.drgpcr.com/newsletter/ - Listen and subscribe to #DrGPCR Podcasts http://www.drgpcr.com/podcast/ - Listen and watch GPCR-focused scientific talks at #VirtualCafe https://www.drgpcr.com/virtual-cafe/

From Arrestins to adhesion GPCRs and creative ways to publish negative data - Dr. Nicole Perry-Hauser04 juil. 202401:13:38


⁠⁠⁠⁠⁠⁠⁠Watch the video version of this podcast episode.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

-------------------------------------------

⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Become a #DrGPCR Ecosystem Member ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

-------------------------------------------

Imagine a world in which the vast majority of us are healthy.

The #DrGPCR Ecosystem is all about dynamic interactions between us working towards exploiting the druggability of # GPCRs. We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.

-------------------------------------------

To build our #GPCR Ecosystem, we created various enabling outlets.

-------------------------------------------

Are you a #GPCR professional?


How do we reward progress in the GPCR field and academia? - Dr. Stuart Maudsley27 juin 202401:39:11


⁠⁠⁠⁠⁠⁠⁠Watch the video version of this podcast episode.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

-------------------------------------------

⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Become a #DrGPCR Ecosystem Member ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

-------------------------------------------

Imagine a world in which the vast majority of us are healthy.

The #DrGPCR Ecosystem is all about dynamic interactions between us working towards exploiting the druggability of # GPCRs. We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.

-------------------------------------------

To build our #GPCR Ecosystem, we created various enabling outlets.

-------------------------------------------

Are you a #GPCR professional?

#156 - Empowering drug discovery for the GPCR community20 juin 202400:53:44

⁠⁠⁠⁠⁠⁠Watch the video version of this podcast episode.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

-------------------------------------------

⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Become a #DrGPCR Ecosystem Member ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

-------------------------------------------

Imagine a world in which the vast majority of us are healthy.

The #DrGPCR Ecosystem is all about dynamic interactions between us working towards exploiting the druggability of # GPCRs. We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.

-------------------------------------------

To build our #GPCR Ecosystem, we created various enabling outlets.

-------------------------------------------

Are you a #GPCR professional?

#155 - Re-cap of Endocrine Metabolic GPCR 202413 juin 202400:27:30

⁠⁠⁠⁠⁠⁠Watch the video version of this podcast episode.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

-------------------------------------------

⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Become a #DrGPCR Ecosystem Member ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

-------------------------------------------

Imagine a world in which the vast majority of us are healthy.

The #DrGPCR Ecosystem is all about dynamic interactions between us working towards exploiting the druggability of # GPCRs. We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.

-------------------------------------------

To build our #GPCR Ecosystem, we created various enabling outlets.

-------------------------------------------

Are you a #GPCR professional?

#154 - Dr. Badr Sokrat06 juin 202401:29:22


⁠⁠⁠⁠⁠Watch the video version of this podcast episode.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

-------------------------------------------

⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Become a #DrGPCR Ecosystem Member ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

-------------------------------------------

Imagine a world in which the vast majority of us are healthy.

The #DrGPCR Ecosystem is all about dynamic interactions between us working towards exploiting the druggability of # GPCRs. We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.

-------------------------------------------

To build our #GPCR Ecosystem, we created various enabling outlets.

-------------------------------------------

Are you a #GPCR professional?

#153 - Dr. Jacek Mokrosinski30 mai 202401:19:11


⁠⁠⁠⁠Watch the video version of this podcast episode.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

-------------------------------------------

⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Become a #DrGPCR Ecosystem Member ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

-------------------------------------------

Imagine a world in which the vast majority of us are healthy.

The #DrGPCR Ecosystem is all about dynamic interactions between us working towards exploiting the druggability of # GPCRs. We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.

-------------------------------------------

To build our #GPCR Ecosystem, we created various enabling outlets.

-------------------------------------------

Are you a #GPCR professional?

© My Podcast Data · Projet indépendant · Données issues d'Apple & Spotify
À proposMéthodologieContactMe soutenirPolitique de confidentialitéMentions légales